Collplant plans clinical trials for dermal filler and advances regenerative implants
Q4 2024 Management View CEO Yehiel Tal highlighted advancements in CollPlant's proprietary photocurable dermal filler, emphasizing its potential as a game-changer in the $6.3 billion market for ...
Hosted on MSN1mon
CollPlant secures U.S. patent for dermal filler
CollPlant specializes in regenerative and aesthetic medicine, leveraging its proprietary plant-based technology ... AGN), an AbbVie company and a leader in the dermal filler market, underscores ...